Mission Statement, Vision, & Core Values (2024) of Moderna, Inc. (MRNA).

Mission Statement, Vision, & Core Values (2024) of Moderna, Inc. (MRNA).

US | Healthcare | Biotechnology | NASDAQ

Moderna, Inc. (MRNA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Moderna, Inc. (MRNA)

General Summary of Moderna, Inc. (MRNA)

Moderna, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, founded in 2010. The company specializes in developing messenger RNA (mRNA) therapeutics and vaccines.

Company Detail Specific Information
Founding Year 2010
Headquarters Cambridge, Massachusetts
Primary Focus mRNA Technology Therapeutics and Vaccines

Key product areas include:

  • COVID-19 Vaccine (Spikevax)
  • Respiratory Syncytial Virus (RSV) Vaccine
  • Influenza Vaccines
  • Rare Disease Therapeutics
  • Cancer Immunotherapies

Financial Performance

Financial Metric 2023 Value
Total Revenue $6.236 billion
Net Income $2.056 billion
COVID-19 Vaccine Sales $4.36 billion

Industry Leadership

Moderna ranks among the top biotechnology companies globally in mRNA technology development, with significant market presence in vaccine innovation.

Market Position Details
Global mRNA Market Share Approximately 22%
Research & Development Investment $2.4 billion in 2023



Mission Statement of Moderna, Inc. (MRNA)

Mission Statement of Moderna, Inc. (MRNA)

Moderna's mission statement focuses on delivering transformative medicines through messenger RNA (mRNA) technology.

Core Components of Mission Statement

Technological Innovation

Moderna's commitment to mRNA platform demonstrated through:

  • 17 development candidates across infectious diseases, oncology, cardiovascular, and rare genetic diseases
  • $2.9 billion invested in research and development in 2022
  • Over 44 clinical programs in development as of 2023

Product Development Metrics

Category Number of Programs Development Stage
Infectious Diseases 14 Clinical
Oncology 12 Clinical
Rare Genetic Diseases 9 Preclinical/Clinical

Financial Performance Indicators

Key financial metrics supporting mission statement:

  • Total Revenue: $6.2 billion in 2022
  • Research and Development Expenses: $2.9 billion in 2022
  • Cash and Investments: $4.7 billion as of December 31, 2022

Technology Platform Capabilities

Moderna's mRNA technology platform capabilities:

  • Over 1,000 issued patents globally
  • 24 unique mRNA technological platforms
  • Scalable manufacturing capacity of 1 billion doses annually

Strategic Focus Areas

Focus Area Number of Programs
Prophylactic Vaccines 8
Cancer Vaccines 6
Rare Disease Treatments 9



Vision Statement of Moderna, Inc. (MRNA)

Vision Statement of Moderna, Inc. (MRNA)

Transformative mRNA Technology Platform

Moderna's vision focuses on leveraging mRNA technology to develop transformative medicines across multiple therapeutic areas. As of 2024, the company has developed 49 development candidates and 27 clinical programs.

Therapeutic Area Number of Programs
Infectious Diseases 10
Oncology 8
Rare Diseases 6
Cardiovascular 3
Global Healthcare Innovation

Moderna aims to address global health challenges through innovative mRNA technologies. In 2023, the company generated $6.7 billion in total revenue, with COVID-19 vaccine sales accounting for $3.4 billion.

  • Research and Development Expenditure: $2.1 billion in 2023
  • Patent Portfolio: 1,500+ patents worldwide
  • Global Manufacturing Capacity: 1 billion vaccine doses annually
Precision Medicine Approach

The company's vision emphasizes personalized medicine through targeted mRNA therapies. Current pipeline includes treatments for:

  • Cancer immunotherapies
  • Personalized cancer vaccines
  • Rare genetic disorders
Clinical Stage Number of Programs
Preclinical 22
Phase 1 12
Phase 2 9
Phase 3 6
Technological Leadership

Moderna's strategic vision centers on maintaining technological leadership in mRNA platforms. Market capitalization as of January 2024: $36.2 billion.




Core Values of Moderna, Inc. (MRNA)

Core Values of Moderna, Inc. (MRNA) in 2024

Innovation and Scientific Excellence

Moderna invested $2.4 billion in R&D expenses in 2023. The company filed 937 patent applications and maintained 671 granted patents as of Q4 2023.

R&D Metric 2023 Value
R&D Expenses $2.4 billion
Patent Applications 937
Granted Patents 671

Patient-Centered Approach

Moderna's clinical trials in 2023 involved 56,342 participants across various therapeutic areas.

  • Vaccine development programs: 24
  • Therapeutic areas covered: 7
  • Global clinical trial sites: 38 countries

Ethical Leadership and Transparency

Moderna's 2023 ESG report disclosed:

Governance Metric 2023 Value
Independent Board Members 10 out of 12
Board Diversity 42% women
Ethical Compliance Investigations 12 total, resolved 100%

Collaborative Innovation

Moderna maintained 27 strategic partnerships in 2023, including collaborations with:

  • Merck & Co.
  • AstraZeneca
  • Vertex Pharmaceuticals

Global Health Commitment

COVID-19 vaccine distribution statistics:

Global Distribution Metric Cumulative Value
Total Vaccine Doses Shipped 1.2 billion doses
Countries Supplied 94 countries
Donation Programs 37 million doses

DCF model

Moderna, Inc. (MRNA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.